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In previous clinical studies, intradermal (i.d.) in-
jection of allergen-derived peptides resulted in 
modulation of surrogate markers of disease in 
allergic asthma; early- and late-phase skin re-
sponses to allergen were reduced (Oldfield et al., 
2002), along with nasal symptoms (Alexander 
et al., 2005a) and airway hyperreactivity (AHR; 
Alexander et al., 2005b). Peptide treatment sup-
pressed allergen-specific T cell proliferation and 
production of IL-4, IL-13, and IFN-, whereas 
IL-10 production was enhanced (Oldfield et al., 
2001; Oldfield et al., 2002). The immunological 
mechanisms responsible have yet to be defined, 
but may include clonal deletion, induction of 
anergy (for review see Schwartz 2003), and/or 
active regulation (Sundstedt et al., 2003; Apostolou 
and Von Boehmer, 2004). We recently demon-
strated induction of functional allergen-specific 
regulatory T cells after peptide therapy (Verhoef 
et al., 2005).
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Treatment of patients with allergic asthma using low doses of peptides containing T cell 
epitopes from Fel d 1, the major cat allergen, reduces allergic sensitization and improves 
surrogate markers of disease. Here, we demonstrate a key immunological mechanism, linked 
epitope suppression, associated with this therapeutic effect. Treatment with selected epitopes 
from a single allergen resulted in suppression of responses to other (“linked”) epitopes 
within the same molecule. This phenomenon was induced after peptide immunotherapy in 
human asthmatic subjects and in a novel HLA-DR1 transgenic mouse model of asthma. 
Tracking of allergen-specific T cells using DR1 tetramers determined that suppression was 
associated with the induction of interleukin (IL)-10+ T cells that were more abundant than 
T cells specific for the single-treatment peptide and was reversed by anti–IL-10 receptor 
administration. Resolution of airway pathophysiology in this model was associated with 
reduced recruitment, proliferation, and effector function of allergen-specific Th2 cells.  
Our results provide, for the first time, in vivo evidence of linked epitope suppression and  
IL-10 induction in both human allergic disease and a mouse model designed to closely 
mimic peptide therapy in humans.
© 2009 Campbell et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Our clinical studies have focused on peripheral blood re-
sponses to allergen before and after therapy. A limitation of 
studying asthmatic human subjects is that it is not possible to di-
rectly examine local allergen-specific T cell responses within 
lung tissue. To address this issue, we have developed a model of 
Fel d 1 (the major allergen of the domestic cat, Felis domesticus)–
induced allergic lung inflammation in a mouse transgenic for the 
human MHC class II molecule (HLA-DR1; DRA/DRB1*0101) 
and lacking endogenous mouse MHC class II (H2-Ao). We 
were thus able to investigate mechanisms of peptide therapy–in-
duced immunomodulation using the same peptides and route of 
treatment as that used in human therapy. Low-dose (1 µg) pep-
tide therapy was used, reflecting our current clinical practice, 
and was substantially lower than previously used in mouse 
models. Immunological mechanisms were investigated by ana-
lyzing T cell responses to treatment peptides and nontreatment 
peptides from the same allergen molecule and using MHC class 
II (HLA-DR1) tetramers.
Here, we provide evidence for the induction of linked epi-
tope suppression in both human and mouse responses, together 
with substantial induction of IL-10 in T cells of mice, which 
was not limited to cells specific for the treatment peptide. In 
mice, reduced Th2 cell recruitment to the lung and suppressed 
effector cell function resulted in IL-10–dependent resolution of 
allergic lung inflammation, directly demonstrating treatment ef-
ficacy of peptide therapy in this model. The common responses 
to cat peptide therapy in humans and mice, as well as clear re-
duction in allergic inflammation in the mouse model, provide 
evidence that peptide therapy suppresses allergic asthma via in-
duction of IL-10 and linked epitope suppression.
RESULTS
Peptide immunotherapy induces linked epitope suppression 
of antigen-specific responses in allergic asthmatic subjects
To determine the effect of Fel d 1 peptide therapy on re-
sponses to Fel d 1 peptides not included in the therapeutic 
cocktail, we examined ex vivo peptide-specific proliferative 
responses and cytokine production from PBMCs of peptide-
treated allergic asthmatics. PBMC proliferative responses to 
each of 16 Fel d 1 peptides (12 peptides from a therapeutic 
peptide vaccine; “treatment peptides,” and 4 Fel d 1 peptides 
not included in the vaccine; “non-treatment peptides”) were 
assessed in a randomized, double-blind, placebo-controlled 
Figure 1. Peptide immunotherapy in cat allergic asthmatic sub-
jects induces linked epitope suppression. PBMCs were isolated before 
and after a randomized, double-blind, placebo-controlled trial of peptide 
immunotherapy and frozen. Cells were thawed and cultured with indi-
vidual peptides and with cat allergen extract for 6 d before quantification 
of proliferation and cytokine release. Assays were performed once on both 
pre- and posttreatment samples. Peptides shown by number on the x axis 
correspond to amino acid sequences in chain 1 (peptides 1–7) and chain 2 
(peptides 8–16) of Fel d 1 sequence as follows: 1:1–17, 2:12–28, 3:23–38, 
4:29–45, 5:39–55, 6:48–63, 7:54–69, 8:1–16, 9:7–23, 10:20–35, 11:29–44, 
12:40–55, 13:48–63, 14:56–71, 15:67–82, 16:77–92. (a) Proliferation data 
were normalized by conversion to stimulation index (SI; cpm for peptide/
allergen culture divided by cpm of medium alone culture). Peptide immuno-
therapy resulted in statistically significant reductions in proliferative  
responses to cat allergen extract and to treatment peptides and nontreat-
ment peptides (peptide number shown in shaded boxes). The response to 
each peptide is represented in paired bars. Pretreatment, open bars; post-
treatment, filled bars. IL-4 (b) and IL-13 (c) production to individual pep-
tides and cat allergen extract was reduced as indicated by statistical 
significance. No significant changes in proliferative or cytokine responses 
to the control antigen–purified protein derivative (PPD) of Mycobacterium 
tuberculosis were observed. Data are median, range, and interquartiles 
(box-and-whisker plot). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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hyperplasia and mucus hypersecretion (Fig. 3 e). This was 
reduced after treatment with Feld1(29–45) (Fig. 3 f). The effect 
of Feld1(29–45) treatment was reflected in relative levels of 
leukocytes in the lung lumen. Eosinophils made up >60% of 
the BAL inflammatory infiltrate, the remaining cells being 
macrophages, lymphocytes, and a few neutrophils. Total 
BAL leukocytes and eosinophils were significantly reduced 
in Feld1(29–45) versus HA(306–318)-treated mice (Fig. 3 g). 
Both total leukocytes and eosinophils were also significantly 
reduced in digested lung tissue after Feld1(29–45) treatment 
(Fig. 3 h). Thus, a single therapeutic i.d. administration of 
Feld1(29–45) was able to significantly reduce allergic lung in-
flammation in both airway lumen and tissue after allergen 
rechallenge weeks later.
To determine whether the reduction in bronchial inflam-
mation was associated with improved lung function in cat 
allergen–sensitized DR1-tg/Ao mice, we measured AHR 
to methacholine by whole body plethysmography 24 h after 
the first allergen rechallenge (d59) in addition to direct mea-
surements of lung airway resistance and dynamic compliance 
in mechanically ventilated mice 24 h after the second aller-
gen rechallenge (d60). Cat allergen sensitization and chal-
lenge resulted in airway inflammation and a methacholine 
dose-dependent increase in enhanced pause (Penh) at day 24 
(unpublished data). Animals were subsequently treated with 
HA(306–318) or Feld1(29–45) and rechallenged with allergen 
4 wk later. i.d. treatment with Feld1(29–45) significantly re-
duced Penh responses at 30 and 100 mg/ml methacholine 
doses to levels observed in unsensitized mice (Fig. 3 i). These 
data were confirmed by lung resistance and compliance mea-
surements at the 100 mg/ml methacholine dose (Fig. 3, j and k). 
Thus, the reduction in cellular and tissue inflammation after 
Feld1(29–45) therapy was associated with a significant improve-
ment in lung function.
trial in 24 cat-allergic asthmatic subjects. Clinical outcomes 
are reported elsewhere (Oldfield et al., 2002). Responses to all 
12 treatment peptides were significantly reduced in the 16 
subjects receiving active treatment, but not in the 8 subjects 
receiving placebo. Strikingly, responses to the four nontreat-
ment peptides were significantly reduced in the active treat-
ment group only (Fig. 1 a). Cytokine secretion followed a 
similar pattern. IL-4 production to all peptides (treatment and 
nontreatment) was significantly reduced in the active treat-
ment, but not the placebo group (Fig. 1 b). IL-13 responses 
were more variable, with those to 6/12 treatment peptides 
significantly reduced, together with all nontreatment peptides 
(Fig. 1 c). IFN- responses were generally low but variable, 
with those to 9/12 treatment peptides significantly reduced, 
together with all nontreatment peptides (unpublished data). 
No significant changes in proliferative or cytokine responses 
to the control recall antigen (in a routinely vaccinated popula-
tion) purified protein derivative of Mycobacterium tuberculosis 
were observed.
Peptide immunotherapy reduces lung inflammation  
and improves lung function in sensitized and rechallenged 
DR1-tg/Ao mice
To investigate the cellular and molecular mechanisms lead-
ing to immunosuppression of allergic responses after peptide 
immunotherapy, we have developed a specific mouse model. 
We generated mice transgenic for human HLA DR1, but 
deficient in mouse MHC class II, thus MHC class II–medi-
ated antigen presentation in the DR1-tg/Ao model was re-
stricted to HLA-DR1–binding peptides. We chose a dosing 
schedule that was similar to that used in our human study 
and used a single peptide (residues 29–45 of chain 1 of the 
cat allergen Fel d 1, referred to here as Feld1[29–45], which was 
also a component of the clinical vaccine) to induce tolerance 
in allergen-primed animals to subsequent inhaled challenge 
with an aqueous extract containing Fel d 1 and other cat 
proteins (Fig. 2; sensitization and treatment protocol). We 
have previously shown that peptide immunotherapy in aller-
gic asthmatic subjects improves surrogate clinical markers of 
airway inflammation (Alexander et al., 2005a; Alexander 
et al., 2005b). Therefore, we determined whether the peptide 
immunotherapy schedule had a similar effect on lung inflam-
mation and function in our mouse model. Mice that were 
sham sensitized but challenged with allergen did not exhibit 
any pulmonary inflammation (Fig. 3 a). Animals treated with 
the control HA(306–318) (residues 306–318 of influenza hem-
agglutinin) peptide showed extensive peribronchial and 
perivascular eosinophilic inflammatory infiltrates comparable 
to those seen in mice sensitized and challenged with cat al-
lergen (Fig. 3 b and not depicted). In contrast, mice treated 
with Feld1(29–45) had substantially reduced airway inflamma-
tion (Fig. 3 c) compared with HA(306–318)-treated animals. 
Importantly, we could assess airway inflammation in both 
the lumen (by lavage) and lung tissue in the mouse model. 
Compared with unsensitized mice (Fig. 3 d), exposure to 
cat allergen in sensitized mice was marked by goblet cell 
Figure 2. Schematic protocol flow chart for cat allergen-induced 
airway disease and therapeutic treatment with Fel d 1 peptide.  
Airway inflammation was induced in DR1-tg/Ao mice sensitized with  
10 µg recombinant Fel d 1 in alum (days 0 and 14) and challenged i.n. with 
250 µg cat allergen extract (days 22, 23, and 24). To induce tolerance, a 
single i.d. injection of 1 µg of Feld1(29–45) (or HA(306–318) as a DR1-binding 
control) was administered (day 25) after establishment of eosinophilic 
inflammation. Mice were rechallenged with cat allergen extract (days 59 
and 60), lung function was analyzed, and the mice were sacrificed (day 
61) for tissue harvest. Unsensitized control mice received PBS in alum  
and were challenged in the same manner as sensitized animals.
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Figure 3. Peptide immunotherapy reduces allergic lung inflammation and improves lung function. MHC II (DR1-tg/A0) mice were sensitized with 
PBS (unsensitized control) or rFel d 1 in alum and allergic inflammation localized to the lung by repeated i.n. challenge with cat allergen extract. Mice were 
treated by i.d. injection of HA(306–318) (control peptide) or Feld1(29–45) (treatment peptide) and rechallenged with cat allergen extract (i.n.). Representative lung 
histology from unsensitized (a and d), allergen-sensitized control peptide-treated (b and e), and allergen-sensitized allergen peptide-treated (c and f) mice. 
Mice were sacrificed 24 h after the final cat allergen challenge. Paraffin-embedded lung was sectioned (4 µM) and stained with hematoxylin and eosin  
(a-c) or periodic acid schiff for detection of mucin (d–f). Representative sections are shown for each treatment group. Bar, 50 µm. Original magnification, 
400×. (g) Airways were lavaged with PBS via a tracheal cannula. BAL cells were transferred to slides by cytocentrifugation and differential cell counts were 
performed by counting eight high power fields (40× magnification; total area, 0.5 mm2 per area randomly selected) and dividing this number by the total 
number of cells per high power field. To obtain absolute numbers of each leukocyte subtype, percentages were multiplied by the total number of cells ob-
tained in the lavage fluid. (h) Single lobes of lung tissue were digested with collagenase and DNase as described in the Materials and methods. Differential 
counts were performed on cytocentrifuge preparations as for BAL. (i) AHR was measured at day 60 by whole-body plethysmography in response to inhaled 
methacholine (3–100 mg/ml) for 1 min. Penh data were confirmed by direct measurement of airway resistance (RL; j) and lung dynamic compliance (Cdyn; k) 
in anesthetized and tracheotomized mice in response to inhaled methacholine (3–100 mg/ml). For i and j, Unsensitized mice are represented by squares, sen-
sitized/HA(306–318) by circles, and sensitized/Feld1(29–45) by triangles. All data are expressed as mean ± SEM. n = 6 mice/group. Two independent experiments 
were performed. *, P < 0.05 for sensitized HA(306–318) versus DR1Feld1-treated mice, Mann-Whitney U test.
Peptide immunotherapy induces linked epitope suppression 
of antigen-specific T cell responses in the mouse lung
To investigate the mechanisms behind the effect of peptide 
immunotherapy on allergic pathophysiology, we studied spe-
cific T cell responses in the lungs of treated and untreated mice. 
Because we were using DR1tg mice we could use an HLA-DR 
tetramer incorporating the treatment peptide (DR1Feld1[29–45]tet-
ramer) to track allergen-specific cells in the lung and to study 
specific responses to allergen. The number of tetramer+ cells in 
the lungs was small. Therefore, to generate a detectable amount 
of cells, samples within each group were pooled and restim-
ulated with recombinant Fel d 1 (rFel d 1) protein in vitro. 
JEM VOL. 206, July 6, 2009 
ARTICLE
1539
of CD4+DR1Feld1(29–45)tetramer+ cells (Fig. 4 a). Feld1(29–45) 
treatment reduced antigen-driven lymphocyte proliferation 
(Fig. 4 b). Cells from unsensitized mice did not proliferate in 
response to rFel d 1. In contrast, cells from sensitized, chal-
lenged, and control peptide–treated mice demonstrated 
Cells were labeled with CFSE to evaluate antigen-specific pro-
liferative responses in Feld1(29–45)-treated versus HA(306–318) (con-
trol peptide)-treated mice. Representative data plots of lung 
tissue digest cultures stained with CD4 and DR1Feld1(29–45)tetra-
mer demonstrate that Feld1(29–45) treatment reduced the number 
Figure 4. Peptide immunotherapy reduces proliferative responses to Fel d 1. Mice were sacrificed at day 61 and cells from collagenase digests of 
lung tissue (cells pooled/treatment group of 6 mice) were labeled with CFSE and restimulated with Fel d 1 for 6 d. Cells were stained with HLA-DR1 tetra-
mers specific for the treatment peptide (DR1Feld1[29–45]tetramer) or a control peptide (DR1A2tetramer) and analyzed by flow cytometry. (a) DR1Feld1(29–45)tet-
ramer and CD4 double staining of cells from unsensitized (left), sensitized and treated with control peptide HA(306–318) (middle), and sensitized mice 
treated with Feld1(29–45) (right). (b) CFSE dilution analysis of total lymphocyte population (defined by scatter) in cells from unsensitized (left), sensitized 
control peptide-treated (middle), and Feld1(29–45)-treated mice (right). (c) CFSE dilution analysis of treatment peptide Feld1(29–45)–specific cells. (top row) 
Proliferation of CFSE-labeled lung digest cells labeled with control tetramer (DR1A2tetramer). (bottom row) Proliferation of CFSE-labeled lung digest cells 
labeled with DR1Feld1(29–45)tetramer. Representative plots are shown from three independent experiments. n = 6/group.
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associated with a significant increase in IL-10 protein in 
bronchoalveolar lavage (BAL) and homogenates of lung tis-
sue (Fig. 6, a and b). As IL-10 can be produced by many cell 
types, we determined whether allergen-specific CD4+ T cells 
contributed to increased IL-10 production. Lung tissue digest 
cells were cultured with rFel d 1 in vitro for 6 d, and then re-
stimulated. Mice that had been treated with Feld1(29–45) had 
a significantly higher proportion of IL-10+ CD4+ cells and 
IL-10+ lymphocytes than control peptide-treated mice (Fig. 6, 
c and d). A substantial proportion of all CD4+ cells and lym-
phocytes stained positive for IL-10 after Feld1(29–45) treatment 
(>10%), indicating that Feld1(29–45) treatment induced a pop-
ulation of IL-10–producing CD4+ T cells that was much 
larger than the pool of cells specific for the treatment peptide 
(2%; Fig. 4).
Active TGF- was measured by ELISA in BAL and lung 
tissue homogenates. Feld1(29–45) treatment had no effect on 
active TGF- levels (Fig. 6 e; BAL data shown). TGF- was 
not detectable by flow cytometry in or on CD4+ T cells (not 
depicted). Foxp3 has been described as marker of regulatory 
T cells, and we were indeed able to detect intracellular Foxp3 
expression in lung tissue digest, BAL, and peribronchial lymph 
node CD4+ cells. However, there was no significant increase 
in numbers of Foxp3+ CD4+ cells from Feld1(29–45)-treated 
compared with HA(306–318)-treated mice (Fig. 6 f; data for 
lung tissue cells shown).
Pulmonary and systemic Th2 responses are reduced  
in peptide-treated mice
Peptide immunotherapy was associated with an improve-
ment in allergen-driven inflammation and lung function, 
both of which are dependent on Th2 cells (Coyle et al., 
1999). Therefore, we assessed the effect of peptide treatment 
on Th2 function and recruitment. Peptide immunotherapy 
was associated with significantly decreased recruitment of 
Th2 cells in BAL and digested lung tissue (Fig. 7), although 
substantial proliferation to rFel d 1, which was markedly re-
duced after Feld1(29–45) treatment.
To determine a mechanistic link between amelioration 
of cat allergy and Feld1(29–45) treatment, we examined relative 
populations of Feld1(29–45)+ and Feld1(29–45)neg cells (i.e., T cells 
specific for the treatment peptide and T cells specific for other 
Fel d 1 epitopes, respectively) in ex vivo cell cultures stained 
with CFSE and stimulated with whole rFel d 1. The combi-
nation of CFSE and tetramer staining of allergen-stimulated 
cells allowed us to identify allergen-specific cycling cells that 
were treatment peptide-specific (tetramer+) and those spe-
cific for other Fel d 1 DR1-restricted epitopes (tetramerneg). 
We were thus able to visualize the effect of treatment with a 
single epitope on the T cell response to other epitopes in the 
same molecule (linked epitopes). Treatment with Feld1(29–45) 
decreased numbers of DR1Feld1(29–45)tetramer+ cells and 
DR1Feld1(29–45)tetramerneg cells proliferating to other DR1- 
restricted epitopes of Fel d 1 (Fig. 4 c). No staining of cells was 
observed with control tetramer (DR1A2tetramer, which con-
tained a DR1-binding peptide from HLA-A2; Fig. 4 c, top) 
or in unsensitized mice (Fig. 4 c, left). Staining of cells with 
DR1Feld1(29–45)tetramer demonstrated that a proportion of pro-
liferating cells in control peptide-treated mice were specific for 
Feld1(29–45). Their numbers were unaffected by control pep-
tide treatment. After treatment with Feld1(29–45), the number 
of DR1Feld1(29–45)tetramer+ cells was reduced (Fig. 4 c, bottom 
right versus middle). Furthermore, the proliferative response 
of DR1Feld1(29–45)tetramerneg cells was also reduced (Fig. 4 c, 
bottom). This is indicative of active regulation through the 
induction of linked suppression (intramolecular tolerance) be-
cause treatment targeting T cells specific for one epitope of a 
molecule down-regulated the response to other epitopes.
Another important observation from this experiment is 
that no increase in DR1Feld1(29–45)tetramer+ noncycling cells 
was observed, suggesting that induction of anergy in airway 
T cells was not a contributing mechanism in this model. The 
possibility that these cells had trafficked to draining lymph 
nodes was investigated by tetramer staining of cell suspen-
sions. Strikingly, there were very few DR1Feld1(29–45)tetramer+ 
cells in restimulated draining lymph node cell cultures com-
pared with lung tissue cell cultures (Fig. 5). Collectively, 
these data in DR1 transgenic mice provide evidence of 
Feld1(29–45) treatment–induced linked epitope suppression as-
sociated with largely resolved lung inflammation and im-
proved lung function.
Cat allergen–sensitized and –challenged DR1-tg/Ao mice 
demonstrate increased IL-10 after peptide immunotherapy, 
but no change in TGF- or Foxp3
Previous studies have implicated IL-10 and TGF- as impor-
tant mediators in the regulation of in vivo immune responses; 
therefore, we investigated whether IL-10 or TGF- expres-
sion were associated with tolerance in our mouse model of 
cat allergy. We have previously reported induction of IL-10 
in human peptide immunotherapy (Oldfield et al., 2002; 
Tarzi et al., 2006). Feld1(29–45) treatment in allergic mice was 
Figure 5. Lung tissue digests, but not draining lymph nodes, con-
tain T cells specific for the treatment peptide. Mice were sacrificed at 
day 61 and cells from draining lymph nodes and collagenase digests of 
lung tissue were restimulated with Fel d 1 for 6 d. Cells were stained with 
HLA-DR1 tetramers specific for the treatment peptide (DR1Feld1[29–45]tetra-
mer) or a control peptide (DR1A2tetramer; not depicted) and analyzed by 
flow cytometry. Representative plots are shown from three independent 
experiments. n = 6 mice/group.
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ment. The chemokines CCL11/eotaxin, CCL17/TARC and 
CCL22/MDC are produced chiefly by epithelial cells and at-
tract CCR3 (receptor for CCL11) and CCR4 (receptor for 
CCL17 and 22) expressing eosinophils and Th2 cells, respec-
tively (Daugherty et al., 1996; Sallusto et al., 1997; Lloyd 
et al., 2000). Hence, we determined by ELISA whether these 
chemokines were altered in mice treated with DR1Feld1. 
CCL11, CCL17, and CCL22 were elevated in sensitized and 
recruitment to draining lymph nodes was unaffected. Num-
bers of CD4+ T cells synthesizing IL-4 or IL-5 were signifi-
cantly reduced in lung tissue digest cells after therapy (Fig. 8). 
Interestingly, no recruitment of these cells was seen in drain-
ing lymph nodes after allergen sensitization and challenge. 
We measured Th2 cytokines (IL-4, IL-5, and IL-13) and the 
Th1 cytokine IFN- in BAL and in digested lung homogenates 
of unsensitized and sensitized mice treated with HA(306–318) 
or Feld1(29–45) before inhaled allergen rechallenge (Fig. 2). 
Allergen sensitization resulted in significant elevation of Th2 
cytokines. Levels of IL-4, IL-5, and IL-13 were elevated in 
sensitized/HA(306–318)-treated mice. Feld1(29–45) administration 
substantially reduced Th2 cytokine levels in the BAL with 
more modest reductions in lung tissue homogenates (Fig. 9, 
a and b). IFN- levels were only marginally elevated in this 
model and not significantly modulated by Feld1(29–45) treat-
Figure 6. Peptide immunotherapy is associated with increased  
IL-10 production, but no role is evident for TGF- or Foxp3. Mice were 
sacrificed at day 61 and subjected to BAL. Individual lobes of lung tissue 
were enzymatically digested to release inflammatory cells. (a) IL-10 levels 
in BAL fluid were quantified by ELISA. (b) IL-10 levels in lung digest ho-
mogenates (100 mg of tissue) were quantified by ELISA. (c) The percent-
age of CD4+ cells within lung tissue digests expressing IL-10 was detected 
by flow cytometry. (d) The percentage of total lymphocytes within lung 
tissue digests expressing IL-10. (e) Levels of active TGF-1 were measured 
in BAL by ELISA. (f) Foxp3 expression in CD4+ lung tissue digest cells was 
measured by flow cytometry. For all graphs, white bars represent re-
sponses of cells from unsensitized mice and black bars and gray bars rep-
resent responses of sensitized HA(306–318)-treated and sensitized 
Feld1(29–45)-treated mice, respectively. P values were determined using 
Mann-Whitney U test. Mean data ± SEM from three independent experi-
ments each with five mice per group.
Figure 7. Peptide immunotherapy reduces Th2 cell recruitment to 
the lung. T1ST2+ (a Th2 cell phenotypic marker) cells were measured in 
the BAL (a), lung tissue digest (b), and peri-bronchial lymph nodes (c) by 
flow cytometry. Mice were sacrificed at day 61, and cells were isolated 
and stained with anti–mouse CD4 and anti–mouse T1ST2 as described in 
the Materials and methods. For BAL and lung tissue digest, data are ex-
pressed as mean T1ST2+/CD4+ cell numbers ± SEM by multiplying the 
percentage expression on live cells by the total cell counts. For lymph 
node cells, data shown are the percentage of expression within the CD4+ 
population. T1ST2 expression on CD4+ cells of unsensitized mice (white 
bars), sensitized/HA(306–318)-treated (black bars), and sensitized/Feld1(29–45)-
treated mice (gray bars). Data are mean ± SEM. n = 5 mice/group and 
data are representative of 4 independent experiments. *, P < 0.05 and  
**, P < 0.01 for sensitized/HA(306–318) versus sensitized/Feld1(29–45) treated  
groups, Mann-Whitney U test.
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Anti–IL-10R treatment increased airway resistance, abrogat-
ing the therapeutic effect of Feld1(29–45) on lung function, 
but was without effect on airway resistance in control mice, 
which remained at basal levels (Fig. 10 a). In addition to rever-
sal of peptide therapy effects on lung function, anti–IL-10R 
treatment was associated with exacerbation of Th2 lung 
inflammation. Significant increases in BAL and lung eosino-
phils (Fig. 10 b), together with increased numbers of T cells 
expressing the Th2 cytokines IL-4 or IL-5 (Fig. 10 c) and the 
Th2 cell marker T1ST2 (Fig. 10 d), were observed. Feld1(29–45) 
therapy was shown to reduce the numbers of proliferating Fel 
d 1–specific T cells, including CD4+DR1Feld1(29–45)tetramer+ 
cells (Fig. 4). Anti–IL-10R treatment reversed this effect and 
restored Fel d 1–stimulated CD4+DR1Feld1(29–45)tetramer+ cell 
numbers (Fig. 10 e). Finally, neutralization of IL-10R in pep-
tide-treated mice also resulted in an elevated systemic Th2 
response, as shown by significantly higher total IgE levels in 
anti–IL-10R–treated mice (Fig. 10 f). Collectively, these data 
indicate that the mechanism of low-dose peptide immuno-
therapy is IL-10–dependent in a wide range of physiological, 
cellular, and humoral parameters.
challenged mice. i.d. treatment with Feld1(29–45) significantly 
reduced levels of these chemokines in the BAL and in lung 
tissue homogenates compared with HA(306–318) treatment 
(Fig. 9, c and d). Elevated systemic IgE is also associated with 
allergic airways disease. In our DR1-tg/Ao model, total se-
rum IgE and Fel d 1–specific IgE were increased in sensitized 
and challenged mice. Treatment with Feld1(29–45) but not 
HA(306–318) significantly reduced levels of IgE in the serum 
(Fig. 9, e and f). Thus, i.d. treatment with Feld1(29–45) reduced 
both systemic and local lung Th2 responses to cat allergen.
Neutralization of IL-10 activity during immunotherapy  
with Feld1(29–45) reverses peptide-induced tolerance
Treatment with Feld1(29–45) reduced cat allergen–stimulated 
Th2 responses systemically and in the lung. Treatment was 
associated with elevated IL-10+ CD4+ T cells in lung tissue. 
To determine whether peptide immunotherapy in this model 
was IL-10 dependent, we neutralized IL-10 activity in vivo 
beginning at the time of peptide-treatment and until cat aller-
gen rechallenge. In vivo administration of anti-IL-10 receptor 
(R) antibody effectively reversed peptide-induced tolerance. 
Figure 8. Peptide immunotherapy reduces proportions of lung 
tissue IL-4+ and IL-5+ CD4+ cells after antigen restimulation in 
vitro. Mice were sacrificed at day 61 and cells from collagenase digests 
of lung tissue were restimulated in vitro with 10 µg/ml rFel d 1 for 6 d. 
Cells were further stimulated with PMA/ionomycin in the presence of 
brefeldin A for 4 h. (a) Percentage of IL-4+ cells CD4+ cells. (b) Percentage 
of IL-5+ cells CD4+ cells are shown with isotype control staining sub-
tracted. Individual data points are shown with medians indicated. n =  
6–10/group from 2 independent experiments. P values were determined 
using Mann-Whitney U test.
Figure 9. Peptide immunotherapy inhibits levels of Th2 cytokines, 
Th2 chemokines, and serum IgE levels. Mice were sacrificed at day 61. 
Serum was obtained by cardiac puncture, BAL was performed to obtain 
BAL fluid, and single lung lobes were harvested and enzymatically di-
gested. (a) BAL fluid and (b) lung digest homogenate cytokines IL-4, IL-5, 
IL-13, and IFN- were measured by ELISA according to manufacturer’s 
protocols. Th2 chemokines CCL11/eotaxin, CCL17/TARC, and CCL22/MDC 
in BAL fluid (c) and lung digest homogenates (d) were measured by ELISA 
according to the manufacturer’s protocols. Total IgE in serum samples  
(e) was quantified by ELISA using paired antibodies according to the 
manufacturer’s protocol. Levels of Fel d 1–specific IgE (f) were measured 
in serum by coating plates with recombinant Fel d 1 (5 µg/ml), incubat-
ing with serum samples, and detecting bound IgE with chromogen-
 labeled anti-IgE. Data are expressed as mean ± SEM. n = 5 mice/group, 
and are representative of three independent experiments. *, P < 0.05 and 
**, P < 0.01 for sensitized/HA(306–318) compared with sensitized/DR1Feld1-
treated mice.
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to allergen (Oldfield et al., 2001; Oldfield et al., 2002; Alexander 
et al., 2005a; Alexander et al., 2005b). Reduced prolifera-
tive responses to allergen were associated with increased IL-10 
production from PBMC and induction of functional CD4+ 
regulatory T cells (Verhoef et al., 2005).
To define the immunological mechanisms underlying the 
effects of peptide immunotherapy, we performed a detailed 
analysis of peptide-specific responses in allergic asthmatic sub-
jects treated with a therapeutic peptide vaccine or with pla-
cebo. Peptide treatment reduced proliferative and cytokine 
responses to both treatment and nontreatment peptides, which 
is indicative of linked epitope suppression, a process through 
which cells rendered tolerant to one epitope suppress the func-
tion of cells specific for other epitopes within the same mole-
cule (Holan and Mitchison, 1983). To determine the functional 
effects of peptide immunotherapy on T cells from the lung 
parenchyma and airways, which are more relevant to clinical 
asthma but cannot be studied in human volunteers, we gener-
ated a novel mouse model of peptide immunotherapy. The 
model was specifically designed to closely mimic our human 
experience. Mice were treated with a single Fel d 1 peptide, 
which forms part of the therapeutic clinical vaccine used in 
human studies. Presentation of the peptide to T cells was re-
stricted by the only MHC class II molecule expressed by the 
mice, the product of a human HLA-DR1 transgene. Using 
this novel model we were able for the first time to directly 
track T cell responses to the treatment peptide using HLA-DR1 
tetramer reagents. Tetramer analysis revealed reduced 
antigen-specific proliferative responses of both DR1Feld1(29–45)tet-
ramer+ cells and tetramerneg cells supporting the observation of 
linked epitope suppression in the clinical study. Given the 
marked reduction in lung inflammation and decreases in Th2 
responses after peptide treatment in the mouse model, it is clear 
that the peptide-specific T cell population was capable of 
down-regulating an established inflammatory response driven 
by multiple T cell epitopes. Indeed, in this model, targeting of 
a relatively rare population of peptide-specific T cells was asso-
ciated with the production of IL-10 by a much larger propor-
tion of the T cell pool. Similar induction of IL-10–producing 
“bystander” T cells was recently reported in a related model 
after transfer of antigen-specific CD4+CD25+ regulatory T cells 
(Kearley et al., 2005). “Infectious” expansion of IL-10–pro-
ducing T cell populations has been described previously in other 
disease scenarios (Qin et al., 1993).
Peptide therapy markedly increased BAL levels of IL-10 
and numbers of IL-10+ T cells in lung tissue, the latter increas-
ing threefold. Lung digest T cells cultured for 7 d with recom-
binant allergen showed lower levels of proliferation after Fel d 1 
peptide treatment compared with control peptide. This may 
have been caused by suppressive effects of increased numbers 
of IL-10+ T cells, and/or caused by a reduction in the num-
bers of allergen-specific T cells through clonal deletion.
PBMCs from allergen peptide-treated subjects, and heat 
shock protein peptide-treated subjects with type I diabetes and 
rheumatoid arthritis, demonstrated enhanced levels of antigen-
stimulated IL-10 production in vitro (Akdis and Blaser, 1999; 
DISCUSSION
Peptide immunotherapy with CD4 T cell epitopes has been 
used extensively in mouse models to prevent and ameliorate 
antigen-specific inflammatory responses and is the subject of 
current clinical trials in allergy and autoimmunity (Larche and 
Wraith, 2005). Improved understanding of mechanisms is 
likely to significantly improve efficacy. In our clinical studies, 
Fel d 1 peptides were delivered i.d., at low dose, to redirect 
allergen-specific responses, decrease symptoms, and reduce in-
flammation. Systemic doses of peptide as low as 5 µg reduced 
skin allergen sensitivity and proinflammatory PBMC responses 
Figure 10. Feld(29–45) peptide immunotherapy is dependent on  
IL-10. Mice were sensitized, allergen-challenged, and treated with 
Feld1(29–45) peptide as described in Fig. 2. Mice were then treated with 
neutralizing antibody to the IL-10 receptor (IL-10R) or an isotype control 
antibody (Ig) weekly from day 25. Mice were rechallenged with cat aller-
gen extract (days 59 and 60), lung function was analyzed, and the mice 
were sacrificed (day 61) for tissue harvest. Unsensitized control mice re-
ceived PBS in alum and were challenged in the same manner as sensitized 
animals. Airway resistance (a) was measured in anesthetized and trache-
otomized mice. BALF and lung tissue cells were isolated as described in 
the Materials and methods. Eosinophil numbers in BAL and lung tissue  
(b) were determined after differential counting of Wright-Giemsa–stained 
cytospins. CD3+CD4+ T cells in lung digests expressing IL-4 and IL-5  
(c) were evaluated by flow cytometry of light-scatter lymphocyte-gated 
cells. Numbers of Th2 cells (CD3+CD4+T1ST2+; d) in the BAL and lung tis-
sue were determined by flow cytometry. Numbers of proliferating CD4+ 
CFSElo DR1Feld1(29–45) tetramer+ cells/mouse (e) were evaluated as described 
in Fig. 4. Total serum IgE (f) was quantified as described in the Materials 
and methods. Data are expressed as mean ± SEM or as individual data 
points with medians indicated. n = 5–12 mice/group. *, P < 0.05; **, P < 
0.01; and ***, P < 0.001 for Ig-treated compared with IL-10R–treated 
Feld1(29–45)-tolerized mice. Two independent experiments were performed, 
with some outcomes performed in one or other of the experiments. Data 
in a, c, and e represent a single experiment; those in panels b, d, and f 
represent two experiments.
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TGF- has been implicated in T cell regulation of immune 
responses through conversion of naive CD25 T cells to regu-
latory CD25+ cells through induction of Foxp3 expression and 
reduction of T cell proliferation (Chen et al., 2003; Apostolou 
and Von Boehmer, 2004). However, in this study, we found 
no change in levels of active TGF-1 in BAL or lung tissue 
homogenates after peptide challenge. This implies that TGF- 
does not have a significant role in suppression of pulmonary 
pathophysiology in this model. We have described similar 
findings in another lung model (Kearley et al., 2005). Because 
Foxp3 expression is thought to be a marker for CD4+CD25+ 
regulatory T cells (Hori et al., 2003) we measured intracellular 
Foxp3 expression in CD4+ T cells isolated from BAL, lung tis-
sue, and peribronchial lymph nodes. Peptide treatment did not 
result in increased numbers of Foxp3+ cells in any of these tis-
sues. These data may discount a role for CD4+CD25+ regula-
tory T cells in peptide-directed resolution of pathophysiology, 
in agreement with our published clinical findings (Smith et al., 
2004), but importantly they highlight a role for IL-10–secret-
ing regulatory cells.
In summary, our data indicate that peptide immunother-
apy ameliorates allergic inflammation in a mouse model via 
an IL-10–dependent mechanism and substantially reduces 
clinical surrogate markers of allergy in human cat allergic 
asthmatics through a process involving linked epitope sup-
pression associated with induction of IL-10. No evidence for 
the induction of clonal T cell anergy was obtained. Treat-
ment of mice was associated with reduced eosinophilia and 
mucus production, improved lung function, reduced Th2 
cytokine and chemokine levels, lower total and specific IgE, 
and reduced numbers of Th2 cells infiltrating the lung tissue 
and BAL. Moreover, we demonstrate, for the first time, the 
direct effect of peptide administration on functional responses 
of lung parenchymal T cells specific for the treatment peptide 
using MHC class II tetramers. The percentage of IL-10–pro-
ducing T cells was markedly enhanced in the lung after pep-
tide therapy and was substantially greater than the percentage 
of cells specific for the treatment peptide, an observation that 
is reminiscent of infectious tolerance. Finally, tolerance in-
duction in the mouse model appeared to be independent of 
TGF- and Foxp3 expression. These studies further our un-
derstanding of mechanisms of peptide-induced tolerance in 
allergic asthma. These results will inform the design and eval-
uation of peptide interventions to ameliorate chronic allergic 
and autoimmune diseases.
MATERIALS AND METHODS
Randomized, double-blind, placebo-controlled trial of peptide 
immunotherapy in allergic asthma
The protocol and clinical outcomes of this trial have been reported previ-
ously (Oldfield et al., 2002). The study was approved by the Royal Bromp-
ton and Harefield National Health Service Trust Ethics Committee. All 
subjects gave written informed consent. For this study, peripheral blood 
samples were obtained before and after therapy. PBMCs were isolated and 
cryopreserved. PBMCs were cultured in 96-well plates for 6 d at a concen-
tration of 106 cells/ml in the presence of 100 µg/ml of each peptide, with 
medium alone and cat dander allergen extract acting as controls. 12 replicate 
Raz et al., 2001; Oldfield et al., 2002; Prakken et al., 2004). 
IL-10+ cells have been found to increase in number in blood 
and tissues taken in clinical studies of grass pollen and insect 
venom immunotherapy (Bellinghausen et al., 1997; Nasser 
et al., 2001; Nouri-Aria et al., 2004) and a higher frequency of 
IL-10–secreting T cells is found in peripheral blood of non-
atopic versus atopic individuals (Akdis et al., 2004). Adoptive 
transfer of IL-10–secreting cells has been shown to ameliorate 
allergic airway inflammation. We have shown that transfer of 
CD4+CD25+ regulatory T cells suppresses allergic lung inflam-
mation by an IL-10–dependent mechanism (Kearley et al., 
2005). Furthermore, IL-10–transduced dendritic cells down-
regulate allergic airway inflammation in mice by induction of 
IL-10–expressing T cells (Henry et al., 2008), and OVA-spe-
cific T cells engineered to express IL-10 also inhibit Th2-in-
duced AHR and inflammation (Oh et al., 2002). In this study, 
neutralization of IL-10 activity via blockade of IL-10R re-
versed peptide-induced tolerance, as shown by lung function 
analysis, elevation of lung and systemic Th2 responses, and 
reversal of peptide treatment effects on proliferation of 
Feld1(29–45)-specific T cells. These results specifically demon-
strate the IL-10 dependence of peptide therapy in this model, 
which does not rely on the transfer of manipulated cells.
We did not observe an increase in the number of 
DR1Feld1(29–45)tetramer+ nondividing cells which would have 
been expected had they been anergized. Thus, we further 
conclude that peptide therapy does not result in the induc-
tion of anergy in the target T cell population, a possibility we 
have been thus far unable to exclude in clinical studies.
Resolution of allergic airway disease in our mouse model 
was achieved with administration of only a single peptide. Chai 
et al. (2004) prevented graft rejection by prophylactic adminis-
tration of 9 µg (3 administrations) of peptide intranasally (i.n.). 
Apostolou and Von Boehmer (2004) induced de novo conver-
sion of naive T cells to CD4+CD25+ antigen-specific regulatory 
cells through chronic exposure (10 µg/d for 14 d) to peptide. By 
directly targeting dendritic cells with an influenza peptide inte-
grated into an antibody to DEC-205, Kretschmer et al. gener-
ated antigen-specific regulatory T cells with the equivalent of 
500 pg of epitope (Kretschmer et al., 2005). Here we report the 
induction of antigen-specific tolerance and resolution of inflam-
mation after the single administration of 1 µg of peptide without 
adjuvant or cell-targeting strategy. Thus, ultra low-dose delivery 
of CD4 T cell epitopes can induce T cells with regulatory func-
tion that are capable of reversing existing pathology.
Using lavage and whole lung tissue, we demonstrated a 
marked reduction in airway and tissue eosinophilia and reduced 
in situ Th2 inflammation. BAL and lung tissue IL-4, IL-5, and 
IL-13 cytokine production was reduced. Local IFN- produc-
tion was not elevated after Feld1(29–45) treatment, suggesting that 
peptide therapy did not result in deviation from a Th2 to a Th1 
response. Levels of the Th2-associated chemokines CCL11, 
CCL17, and CCL22 were also significantly decreased. Possibly 
as a direct result of this, we observed fewer CD4+ T cells ex-
pressing IL-4 and IL-5 and reduced recruitment of Th2 cells to 
lung tissue and BAL after peptide treatment.
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as described previously (Hamelmann et al., 1997). In select experiments, 
AHR was also measured at day 25, 24 h after the i.n. challenge on day 24. 
Penh data were confirmed by direct measurement of lung resistance and dy-
namic compliance in anesthetized and tracheotomized mice in response to 
inhaled methacholine at concentrations of 3–100 mg/ml using a Buxco 
Technologies system in a modified version of previously described methods 
(Martin et al., 1988).
Cell recovery
Airway lumen. BAL was performed as previously described (Gonzalo 
et al., 1996). Airways were lavaged three times with 0.4 ml PBS via a tracheal 
cannula. BAL fluid was centrifuged (700 g, 5 min, 4°C), and cells were trans-
ferred to slides by cytocentrifugation (5 × 104 cells/slide). Differential cell 
counts were performed on Wright-Giemsa–stained (Shandon) cytospins. 
Differential cell counts were determined by counting 8 high power fields 
(40× magnification; total area 0.5 mm2 per area randomly selected), and di-
viding this number by the total number of cells per high power field. To ob-
tain absolute numbers of each leukocyte subtype, percentages were multiplied 
by the total number of cells obtained in the lavage fluid. All differential 
counts were performed blind and in a randomized order at the end of the 
study by the same observer.
Lung parenchyma. To disaggregate cells from the lung tissue, one lobe 
(100 mg) was incubated (37°C) for 1 h in digest reagent: 30 mg/ml colla-
genase (type D; Boehringer Mannheim), 5 mg/ml DNase (type 1; Boeh-
ringer Mannheim), 100 U/ml penicillin, and 100 µg/ml streptomycin 
(Invitrogen) in RPMI 1640(Sigma-Aldrich)/10% FCS. The recovered cells 
were filtered through a 70-m nylon sieve (Falcon; Marathon Laboratory 
Supplies), washed twice, resuspended in RPMI 1640/10% FCS, and counted 
in a hemocytometer. Cytocentrifuge preparations were made and Wright-
Giemsa stained, and differential counts were performed as for BAL.
Peribronchial lymph nodes. Draining lymph nodes were dissected out, 
teased apart, and passed through a 70-m nylon sieve to generate single-cell 
suspensions. Cells were resuspended in complete culture medium: RPMI 
1640/10% FCS, supplemented with 100 U/ml penicillin, 100 µg/ml strep-
tomycin, and 2 mM l-glutamine (Invitrogen).
Flow cytometry
Surface marker staining. Suspensions of cells from lung tissue, lymph 
nodes, and BAL were stained with fluorescently labeled antibodies in PBS 
containing 1% FCS and 0.1% sodium azide. To reduce nonspecific binding, 
cells were incubated with rabbit serum (Sigma-Aldrich) for 15 min before 
staining. For cell surface staining, anti–mouse CD4-APC (BD) and anti–
mouse T1ST2-FITC (Morwell Diagnostics) were used.
Foxp3 expression. Intracellular Foxp3 expression in CD4+ cells was de-
tected using an anti–mouse Foxp3 antibody kit (eBioscience) according to 
the manufacturer’s instructions.
Intracellular cytokines. Cells from lung tissue or lymph nodes were first 
restimulated with 10 µg/ml recombinant Fel d 1 in vitro at 5 × 105 cells/well 
in complete RPMI 1640 in round-bottom 96-well plates at 37°C for 6 d to 
preferentially expand cat allergen–specific T cells. Cells were then treated 
with PMA/ionomycin (10 ng/ml and 1 µg/ml; Merck Biosciences) in the 
presence of brefeldin A (Sigma-Aldrich) for 4 h. Cells were stained with 
anti–CD4-APC fixed and permeabilized in 0.5% saponin (Sigma-Aldrich) 
before intracellular staining with phycoerythrin (PE)-conjugated anti-cyto-
kine antibodies. Cells were stained with anti–mouse IL-4, IL-5, IL-10 and 
appropriate isotype controls (all from BD). PE-labeled anti–human TGF- 
(IQ Products), which cross reacts with mouse TGF- (Ostroukhova et al., 
2004), was used to detect surface TGF- and, after permeabilization, intra-
cellular TGF-.
wells were cultured for each condition. Proliferative responses were evalu-
ated by [3H]thymidine incorporation. For cytokine analysis, cells were cul-
tured with medium, individual peptides or allergen at a concentration of 
5 × 106 cells/ml. Supernatants were harvested at 6 d and frozen. Cytokine 
production was measured by ELISA (Pelikine).
Transgenic mice
HLA-DR1 (DRA*0101/DRB1*0101) transgenic mice on a FVB/N back-
ground were described previously (Altmann et al., 1995). DR1 expression in 
these animals mirrors that of mouse MHC II, and antigen presentation to 
mouse T cells occurs. DR1 transgenic mice were crossed for eight genera-
tions with C57BL/6 Ao mice to yield animals on a C57BL/6 background 
with no endogenous mouse MHC II (DR1-tg/Ao). Polymerase chain re-
action was routinely used to confirm the presence of HLA-DRA1*0101 and 
HLA-DRB1*0101 and the absence of endogenous H2-A in mice. 8–12-
wk-old age, sex, and weight-matched animals were used in all experiments. 
All animal procedures were approved by the UK Home Office. UK Home 
Office regulations for animal welfare, based on the Animals (Scientific Pro-
cedures) Act 1986, were strictly observed.
Allergens and peptides
Recombinant Fel d 1 was prepared as described previously (Gronlund et al., 
2003). Cat allergen extract (predominantly Fel d 1, but also containing other 
cat proteins) was obtained from Laboratorios Leti. Peptide sequences for the 
clinical study were: Fel d 1 chain 1 (1–17) EICPAVKRDVDLFLTGT, (12–28) 
FLTGTPDEYVEQVAQY, (23–38) EQVAQYKALPVVLENA, (29–45) 
KALPVVLENARILKNCV, (39–55) RILKNCVDAKMTEEDKE, (48–63) 
KMTEEDKENALSLLDK, (54–69) KENALSVLDKIYTSPL, Fel d 1 chain 
2 (29–44) LTKVNATEPERTAMKK, (40–55) TAMKKIQDCYVENGLI, 
(56–71) SRVLDGLVMTTISSSK, (67–82) ISSSKDCMGEAVQNTV, and 
(77–92) AVQNTVEDLKLNTLGR. The treatment peptide for the mouse 
model Feld1(29–45) (residues 29–45 of Fel d 1 chain 1; KALPVVLENARI-
LKNCV) was previously shown to be HLA-DR1 restricted (Haselden et al., 
1999). Peptide HA(306–318) (residues 306–318 of influenza virus hemaggluti-
nin; PKYVKQNTLKLAT) was used as a DR1-binding peptide control 
(Stern et al., 1994). Peptides were synthesized by F-moc chemistry at the 
Peptide Synthesis Unit, Medical Research Council Clinical Sciences Centre, 
Imperial College, London, UK.
Allergen-induced airway inflammation and  
peptide-induced tolerance
Before therapeutic treatment with Feld1(29–45) allergic airway disease was in-
duced in DR1-tg/Ao mice by sensitization to Fel d 1, followed by inhaled 
challenge with cat allergen extract to localize inflammation to the lung tissues 
(experiment flow chart given in Fig. 2). Mice were sensitized by injection of 
10 µg Fel d 1/mouse in 0.2 ml of alum (Au-Gel-S; Serva Electrophoresis) i.p. 
on days 0 and 14. Unsensitized (control) mice received the same volume of 
PBS in alum. Mice were challenged i.n. under halothane anesthesia, with 25 µl 
PBS containing 250 µg cat allergen extract or 25 µl PBS alone in the case of 
unsensitized controls on days 22, 23, and 24. Some mice were sacrificed on day 
25 to confirm the presence of eosinophilic lung inflammation. To induce tol-
erance in mice with established airways disease, a single i.d. injection of 1 µg 
Feld1(29–45) (or peptide control, HA(306–318)) was administered on day 25. In se-
lect experiments, mice were treated weekly with 250 µg of anti–IL-10R anti-
body (1B1.3), or isotype control antibody on days 32, 39, 46, 53, and 58. All 
mice were challenged again i.n. with cat allergen extract on day 59 and 60. 
Immediately before the second of these challenges, AHR was assessed. 24 h 
after the last challenge, airway resistance and dynamic compliance were ana-
lyzed and mice were killed by exsanguination under terminal anesthesia. Blood, 
BAL, lung tissue, and draining lymph nodes were taken for analysis.
Measurement of airway function
AHR was measured at day 60 by recording respiratory pressure curves by 
whole-body plethysmography (Buxco Technologies) in response to inhaled 
methacholine (Sigma-Aldrich) at concentrations of 3–100 mg/ml for 1 min, 
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mediating linked suppression of immune responses elicited by third-
party H-2 alloantigens. Eur. J. Immunol. 13:652–657. 
Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell 
development by the transcription factor Foxp3. Science. 299(5609): 
1057–1061. 
Kearley, J., J.E. Barker, D.S. Robinson, and C.M. Lloyd. 2005. Resolution 
of airway inflammation and hyperreactivity after in vivo transfer of 
CD4+CD25+ regulatory T cells is interleukin 10 dependent. J. Exp. 
Med. 202:1539–1547. 
CFSE and MHC II tetramer staining. For the detection of antigen-specific 
cell proliferation, 2.5 × 106 cells of each sample (pooled/treatment group) were 
labeled with CFSE (Invitrogen), as previously described (Verhoef et al., 2005). 
CFSE-treated cells were cultured with 10 µg/ml recombinant Fel d 1, as de-
scribed in the previosu paragrph, for 6 d before staining with MHC class II 
(HLA-DR1) tetramers specific for either the treatment peptide (DR1Feld1[29–45] 
tetramer; peptide KALPVVLENARILKNCV) or an irrelevant control pep-
tide from HLA-A2 (DR1A2tetramer; peptide VGSDWRFLRGYHQYA). 
Biotinylated DR1 complexes were prepared as described previously (Cameron 
et al., 2002). Tetramers were formed by stepwise addition of fluorescently la-
beled streptavidin-PE (Biosource International). Cells (5 × 105) were mixed 
with DR1 tetramers for 4 h at 37°C, chilled for 5 min, stained with anti–mouse 
CD4-APC for 30 min, washed, and fixed. Flow cytometric analysis was per-
formed using a FACSCalibur cytometer and CellQuest software (BD). A pri-
mary gate was set on lymphocytes, as defined by light scatter, and a secondary 
gate was set on the CD4+ population.
Cytokine analysis
Cytokines were analyzed in BAL samples and lung tissue homogenate superna-
tants. Lung tissue was homogenized at 100 mg/ml in HBSS (Invitrogen) in the 
presence of protease inhibitors (Complete mini protease inhibitor cocktail; Roche). 
Homogenates were centrifuged at 500 g for 10 min, and supernatants were col-
lected. Paired antibodies for mouse IFN-, IL-4, TGF- (BD), IL-5 (Endogen), 
eotaxin/CCL11, and TARC/CCL17 (R&D Systems) were used in standardized 
ELISAs according to the manufacturers’ protocols. CCL22 levels were measured 
using a sandwich ELISA generated by coating ELISA plates with anti–mouse 
MDC (a gift from ICOS Corp.) and detecting bound antibody with biotinylated 
anti–mouse MDC (R&D Systems) against a standard curve generated using re-
combinant MDC (R&D Systems) as previously described (McMillan et al., 2004). 
Kits to measure IL-10 and IL-13 (eBioscience and R&D Systems) were used ac-
cording to the manufacturers’ protocols.
IgE measurements
Total IgE in serum samples was quantified by ELISA using paired antibodies ac-
cording to the manufacturer’s protocol (BD). Levels of Fel d 1–specific IgE were 
measured in serum by coating plates with recombinant Fel d 1 (5 µg/ml), incu-
bating with serum samples, and detecting bound IgE as per the total IgE ELISA.
Statistical analysis
For peripheral blood studies, data were tested for normality with a modified 
Shapiro-Wilks test. Significance of changes within groups was tested with a 
Wilcoxon’s rank sum test. Data are expressed as mean ± SEM for bar graphs 
and medians for scatter plots. Statistical significance was accepted when P ≤ 
0.05 using the Mann-Whitney U test.
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